The estimated Net Worth of Parag Suresh Shah is at least $1.02 ezer dollars as of 9 December 2022. Parag Shah owns over 25,500 units of Bellerophon Therapeutics Inc stock worth over $1,020 and over the last 8 years he sold BLPH stock worth over $0. In addition, he makes $0 as Vice President - Business Operations at Bellerophon Therapeutics Inc.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Parag Shah BLPH stock SEC Form 4 insiders trading
Parag has made over 1 trades of the Bellerophon Therapeutics Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 25,500 units of BLPH stock worth $1,020 on 9 December 2022.
The largest trade he's ever made was exercising 25,500 units of Bellerophon Therapeutics Inc stock on 9 December 2022 worth over $1,020. On average, Parag trades about 1,594 units every 0 days since 2016. As of 9 December 2022 he still owns at least 25,500 units of Bellerophon Therapeutics Inc stock.
You can see the complete history of Parag Shah stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Parag Shah biography
Dr. Parag Shah Ph.D. serves as Vice President - Business Operations of the Company. He is with responsibilities for Project Management, Supply Distribution, Pre-Clinical and Business Development activities. Prior to joining Bellerophon, Dr. Shah was Principal Scientist at Pfizer from 2004 through 2010 where he was responsible for leading multiple parenteral and liquid formulation development teams. In addition, Dr. Shah was a member of multiple Limited Duration Teams including serving as Pfizer’s Team Lead for the Nanoparticle Network responsible for internal and external evaluation of nanoparticle technologies. Dr. Shah joined Ikaria as Parenteral Development Lead in 2010 and assumed additional responsibilities in 2012 as Director, Pharmaceutical Science, covering both Pharmaceutical Development and Clinical Supply Management. Dr. Shah received his Bachelor’s degree from Carnegie Mellon and his Ph.D. in Chemical Engineering from The University of Texas at Austin.
How old is Parag Shah?
Parag Shah is 43, he's been the Vice President - Business Operations of Bellerophon Therapeutics Inc since 2016. There are 14 older and 3 younger executives at Bellerophon Therapeutics Inc. The oldest executive at Bellerophon Therapeutics Inc is Peter Fernandes M. Pharm, 66, who is the Interim Principal Exec. Officer, Chief Regulatory & Safety Officer.
What's Parag Shah's mailing address?
Parag's mailing address filed with the SEC is 20 INDEPENDENCE BLVD., SUITE 402, WARREN, NJ, 07059.
Insiders trading at Bellerophon Therapeutics Inc
Over the last 10 years, insiders at Bellerophon Therapeutics Inc have traded over $8,853,497 worth of Bellerophon Therapeutics Inc stock and bought 9,412,012 units worth $57,370,250 . The most active insiders traders include Robert Nelsen, Adam Weinstein és Associates Iv L P Venrock H.... On average, Bellerophon Therapeutics Inc executives and independent directors trade stock every 61 days with the average trade being worth of $10,679. The most recent stock trade was executed by Capital Management Lp Puiss... on 13 October 2023, trading 1,076,841 units of BLPH stock currently worth $107,684.
What does Bellerophon Therapeutics Inc do?
bellerophon therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. our mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need.
What does Bellerophon Therapeutics Inc's logo look like?
Complete history of Parag Shah stock trades at Bellerophon Therapeutics Inc
Bellerophon Therapeutics Inc executives and stock owners
Bellerophon Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Fabian Tenenbaum,
Chief Executive Officer, Chief Financial Officer, Chief Business Officer, Director -
Peter Fernandes,
Chief Regulatory and Safety Officer -
Assaf Korner,
Chief Financial Officer, Secretary -
Peter Fernandes M. Pharm,
Interim Principal Exec. Officer, Chief Regulatory & Safety Officer -
Martin Dekker,
Vice President - Engineering and Manufacturing -
Jonathan Peacock,
Chairman of the Board -
Crispin Teufel,
Independent Director -
Mary Cloyd,
Independent Director -
Naseem Amin,
Independent Director -
Andre Moura,
Independent Director -
Theodore Wang,
Independent Director -
Scott Bruder,
Independent Director -
Matthew Bennett,
Independent Director -
Wassim Fares,
Chief Medical Officer. -
Amy Edmonds,
Vice President - Clinical Operations and Administration -
Parag Shah,
Vice President - Business Operations -
Dr. Edwin L. Parsley,
Acting Chief Medical Officer -
Dr. Parag Suresh Shah,
VP of Bus. Operations -
Nicholas Laccona,
Principal Financial & Accounting Officer and Sec. -
Cross Border Opportunities ...,
-
Megan Schoeps,
Principal Financial Officer -
Matthew S. Holt,
Director -
Deborah Quinn,
Chief Medical Officer -
Adam Weinstein,
Director -
Daniel Tasse,
Director -
Mountain Investments Ii, Ll...,
-
Life Science Opportunities ...,
-
Associates Iv L P Venrock M...,
-
Associates Iv L P Venrock H...,
-
Associates Iv L P Venrock P...,
-
Associates Iv L P Shah Nimi...,
-
Associates Iv L P Venrock P...,
-
Associates Iv L P Venrock H...,
-
Jens Luehring,
Director -
Venture Fund Vi Lparch Vent...,
-
Martin Meglasson,
Chief Scientific Officer -
Mountain Investments Ii, Ll...,
-
Manesh Naidu,
Chief Business Officer -
Robert Nelsen,
Director -
North America, Inc. Linde,
10% owner -
Amit Agrawal,
Chief Operating Officer -
David Abrams,
Treasurer -
R Scott Huennekens,
Director -
Reinilde Heyrman,
Chief Clinical Dev. Officer -
Associates Iv L Pvenrock En...,
-
Life Science Opportunities ...,
-
Nicholas Laccona,
FINANCIAL OFFICER, (PFO & PAO) -
Capital Management Lp Puiss...,
-
Life Science Opportunities ...,
-
Bobae Kim,
VP Reg. Affairs & Quality